Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective. Androgen deficiency is common among men who use opioids daily for chronic pain. In previous studies, we found that long-acting opioids are associated with greater odds of androgen suppression than equipotent doses of short-acting opioids. Here we examined whether specific commonly prescribed opioids were associated with greater odds of androgen deficiency compared to hydrocodone. Design. Retrospective cohort study. Setting and Patients. Within a large, integrated health care delivery system, this study was comprised of men ages 18–80 on a stable regimen of a single opioid for chronic non-cancer pain. Methods. Morning serum total testosterone levels were measured in subjects prescribed one opioid for at least 90 days. The association between individual opioids and androgen deficiency was assessed with logistic regression, controlling for dose, obesity, age, hypertension, hyperlipidemia, and diabetes, using hydrocodone as a referent. Results. This study included 1,159 men. Men on fentanyl (odds ratio [OR] 25.7, 95% CI 2.82–234.97), methadone (OR 7.33, 95% CI 3.29–16.33), or oxycodone (OR 3.15, 95% CI 1.87–5.33) were more likely to be androgen deficient than men on hydrocodone. Increases in dose affected the odds of androgen deficiency differently for different opioids. Increased doses of hydrocodone (OR 1.18 per 10-mg increase in drug, 95% CI 1.09–1.28) and oxycodone (OR 1.01, 95% CI 1.00–1.02) were associated with increased odds of androgen deficiency. Conclusions. Our results suggest that certain opioids are associated with increased odds of androgen deficiency compared with hydrocodone. Transdermal fentanyl, methadone and oxycodone were associated with higher odds of androgen deficiency than hydrocodone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Androgens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
Rao, P. M., Kelly, D. M., & Jones, T. H. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.122 · Cited by 292
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236
Elucidating risk factors for androgen deficiency associated with daily opioid use
Rubinstein, A., & Carpenter, D. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.015 · Cited by 53
Self-citationDaniell, H. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.3.338-a · Cited by 52
Research works printed but not linked: 21
- Grosset, 2005, Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: Two randomized controlled trials, J Pain Symptom Manage, 29, 584, 10.1016/j.jpainsymman.2004.10.008 · DOI
- Hale, 1999, Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain, Clin J Pain, 15, 179, 10.1097/00002508-199909000-00004 · DOI · Paper page
- Stambaugh, 2001, Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients, J Clin Pharmacol, 41, 500, 10.1177/00912700122010375 · DOI · Paper page
- Wilsey, 2009, Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: A randomized cross-over trial, Pharmacol Biochem Behav, 94, 98, 10.1016/j.pbb.2009.07.014 · DOI
- Mattia, 2012, Non-analgesic effects of opioids: The interaction of opioids with bone and joints, Curr Pharm Des, 18, 6005, 10.2174/138161212803582487 · DOI
- Tuck, 2009, Testosterone, bone and osteoporosis, Front Hormone Res, 37, 123, 10.1159/000176049 · DOI · Paper page
- Rubinstein, 2013, Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids, Clin J Pain, 29, 840, 10.1097/AJP.0b013e31827c7b5d · DOI · Paper page
- Pereira, 2001, Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing, J Pain Symptom Manage, 22, 672, 10.1016/S0885-3924(01)00294-9 · DOI · Paper page
- Kuczmarski, 1997, Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994), Obesity Res, 5, 542, 10.1002/j.1550-8528.1997.tb00575.x · DOI · Paper page
- Moffet, 2009, Cohort profile: The Diabetes Study of Northern California (DISTANCE)–Objectives and design of a survey follow-up study of social health disparities in a managed care population, Int J Epidemiol, 38, 38, 10.1093/ije/dyn040 · DOI · Paper page
- Jones, 2010, Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome, J Diabetes, 2, 146, 10.1111/j.1753-0407.2010.00085.x · DOI · Paper page
- Kang, 2013, Beyond the male sex hormone: Deciphering the metabolic and vascular actions of testosterone, J Endocrinol, 217, C1, 10.1530/JOE-13-0052 · DOI
- Muraleedharan, 2010, Testosterone and the metabolic syndrome, Ther Adv Endocrinol Metabol, 1, 207, 10.1177/2042018810390258 · DOI
- Kelly, 2013, Testosterone: A metabolic hormone in health and disease, J Endocrinol, 217, R25, 10.1530/JOE-12-0455 · DOI · Paper page
- Mendelson, 1975, Effects of heroin and methadone on plasma cortisol and testosterone, J Pharmacol Exp Ther, 195, 296, 10.1016/S0022-3565(25)30341-1 · DOI · Paper page
- Azizi, 1973, Decreased serum testosterone concentration in male heroin and methadone addicts, Steroids, 22, 467, 10.1016/0039-128X(73)90002-0 · DOI
- Cicero, 1975, Function of the male sex organs in heroin and methadone users, N Engl J Med, 292, 882, 10.1056/NEJM197504242921703 · DOI · Paper page
- Roberts, 2002, Sex hormone suppression by intrathecal opioids: A prospective study, Clin J Pain, 18, 144, 10.1097/00002508-200205000-00002 · DOI · Paper page
- Kelly, 2013, Testosterone: A vascular hormone in health and disease, J Endocrinol, 217, R47, 10.1530/JOE-12-0582 · DOI · Paper page
- Baumblatt, 2014, High-risk use by patients prescribed opioids for pain and its role in overdose deaths, JAMA Int Med, 174, 796, 10.1001/jamainternmed.2013.12711 · DOI · Paper page
- Pedersen, 2014, Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review, Acta Anaesthesiol Scand, 58, 390, 10.1111/aas.12279 · DOI
Cited by
Opioids and their endocrine effects: a systematic review and meta-analysis
de Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz022 · Cited by 139
Opioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
MECHANISMS OF ENDOCRINOLOGY: endocrinology of opioids
Fountas, A., Chai, S. T., Kourkouti, C., & Karavitaki, N. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0270 · Cited by 60
The effect of opiates on bone formation and bone healing
Coluzzi, F., Scerpa, M. S., & Centanni, M. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00585-4 · Cited by 55
Prevalence of opioid-induced adrenal insufficiency in patients taking chronic opioids
Li, T., Cunningham, J. L., Gilliam, W. P., Loukianova, L., Donegan, D. M., & Bancos, I. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa499 · Cited by 51
Metadata
- Authors
- Rubinstein, A. L., & Carpenter, D. M.
- Venue
- Pain Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-01
- Volume
- 18
- Issue
- 4
- Pages
- 637-644
- ISSN
- 1526-2375 (ISSN-L)
- 1526-4637
- OpenAlex
- W2518204729
- Cited by
- 44
- References
- 7
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis. https://app.cochat.ai/papers/10.1093/pm/pnw182
- The paper
- Rubinstein, A. L., & Carpenter, D. M. (2017). Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis. Pain Medicine. https://doi.org/10.1093/pm/pnw182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.